Failing myocardial tissue

Failing myocardial tissue refers to the heart muscle in a state of chronic dysfunction, where it is unable to pump sufficient blood to meet the body's metabolic requirements. This condition is characterized by significant pathological remodeling, including cardiomyocyte hypertrophy, increased interstitial fibrosis, and alterations in the extracellular matrix (StatPearls, 2023). At the cellular level, the failing myocardium exhibits impaired calcium handling, mitochondrial dysfunction, and a shift in metabolic substrate utilization (PubMed, PMC4315670). While failing myocardial tissue is a pathological state rather than a single molecular target, it is the site of action for a wide range of cardiovascular therapies. Drugs such as ACE inhibitors, beta-blockers, and SGLT2 inhibitors interact with specific receptors and enzymes within this tissue to reduce wall stress, improve contractility, and slow the progression of heart failure (NIH, 2022). Understanding the complex biological environment of the failing heart is essential for the development of regenerative and precision medicine approaches.

Other names

Heart failure tissueFailing heartMyocardial failureDysfunctional myocardium

Therapeutic agents acting on failing myocardial tissue work by modulating neurohormonal pathways (RAAS and sympathetic nervous system inhibition), improving hemodynamic loading conditions, enhancing calcium sensitivity, or altering metabolic substrate utilization to improve cardiac efficiency and reduce pathological remodeling.